CV DRUG FAILS TO PASS EUROPE REVIEW

CV Therapeutics Inc., a developer of drugs to treat heart disease, said Tuesday that European regulators demanded further trials for its experimental drug to treat chronic angina -- a condition in which the heart muscle does not get enough blood -- before they will consider approving the therapy. Shares of the company shed $2.48, or 9.6 percent, to $23.42 in aftermarket trading, after closing up 27 cents to $25.90 on the Nasdaq.

Forbes (http://www.forbes.com/entrepreneurs/feeds/ap/2005/10/25/ap2298911.html)